{
  "abstract": "Background\n\nIn the OlympiA trial, adjuvant olaparib improved survival in patients with germline BRCA1/BRCA2 mutations (gBRCAm) and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC). This analysis presents real-world data from the French-funded early access program for adjuvant olaparib.Patients and methods\n\nEligible adults had gBRCAm and high-risk, HER2-negative eBC, and had received neoadjuvant/adjuvant chemotherapy plus local treatment. Data on olaparib dosing, adverse events (AEs), and health-related quality of life (QoL) were collected during the 12-month treatment period.Results\n\nBetween March 2022 and September 2024, 320 treatment access requests were submitted, of which 308 were approved, with treatment for 217 of the 308 patients (70.5%) at a median follow-up of 10.1 months. Triple-negative tumors were reported in 182 of 308 patients (59.1%) and hormone receptor-positive/HER2-negative tumors in 126 (40.9%). Median age was 45 years (range, 24-82). Most treated patients (208 of 217; 95.9%) started olaparib at 300 mg twice daily. Treatment changes occurred in 139 of 217 patients (64.0%), including interruptions (73 of 217; 33.6%) and dose modifications (66 of 217; 30.4%). Treatment-related AEs occurred in 68 of 217 patients (31.3%), serious AEs in 19 of 217 (8.7%), and AE-related discontinuations in 22 of 217 (10.1%). Two non-olaparib-related deaths occurred and no myelodysplastic syndrome/acute myeloid leukemia was reported. QoL data were available for 85 patients at baseline, decreasing to 26 at month 12. Median global health status/QoL score remained stable throughout treatment. Disease recurrence occurred in 5 of 217 patients (2.3%).Conclusions\n\nThese real-world findings support adjuvant olaparib as standard-of-care in patients with gBRCAm and high-risk, HER2-negative eBC, with no new safety signals.",
  "abstract_shown": true,
  "affiliations": [
    "Medical Oncology Department, Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, Nantes Université, Nantes, France.",
    "Department of Medical Oncology, Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.",
    "Medical Oncology Department, Centre François Baclesse, Caen, France.",
    "Medical Oncology Department, Centre Henri Becquerel, Rouen, France.",
    "Department of Oncology, Oncology Medical Affairs, AstraZeneca SAS, Courbevoie, France."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 13,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "J-S Frenel"
    },
    {
      "affs": [
        1
      ],
      "name": "A Gonçalves"
    },
    {
      "affs": [
        0
      ],
      "name": "J Quintin"
    },
    {
      "affs": [
        2
      ],
      "name": "A Johnson"
    },
    {
      "affs": [
        3
      ],
      "name": "C Alexandru"
    },
    {
      "affs": [
        3
      ],
      "name": "N Olympios"
    },
    {
      "affs": [
        3
      ],
      "name": "O Rigal"
    },
    {
      "affs": [
        4
      ],
      "name": "C Bonnard"
    },
    {
      "affs": [
        4
      ],
      "name": "A Lahouegue"
    },
    {
      "affs": [
        4
      ],
      "name": "F Lazreg"
    },
    {
      "affs": [
        4
      ],
      "name": "D Suau"
    },
    {
      "affs": [
        4
      ],
      "name": "A Debbache"
    },
    {
      "affs": [
        1
      ],
      "name": "A de Nonneville"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/17f31w4j25509.bib",
  "cited_by": 0,
  "doi": "10.1016/j.esmorw.2026.100793",
  "fulltext_url": "https://europepmc.org/articles/PMC13695237",
  "id": "17f31w4j25509",
  "issns": [
    "2949-8201"
  ],
  "landing_url": "https://europepmc.org/article/MED/42927328",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|PARP inhibition in cancer therapy"
    ]
  ],
  "openalex": "W7214048000",
  "pdf_url": "https://europepmc.org/articles/PMC13695237?pdf=render",
  "pmcid": "PMC13695237",
  "pmid": "42927328",
  "published": "2026-09-22",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/17f31w4j25509.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:21:18Z",
      "native_id": "MED:42927328",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42927328"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|PARP inhibition in cancer therapy",
      "subfield": "oncology"
    }
  ],
  "title": "Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program.",
  "title_text": "Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:21:18Z",
  "url": "https://research.draconitic.com/paper/17f31w4j25509",
  "venue": "ESMO real world data and digital oncology",
  "versions": []
}